Story
Arcadis Stock Hits 9-Month High on Jefferies 'Buy' Upgrade

Summary
Shares in the Dutch engineering firm Arcadis surged after Jefferies upgraded the stock to 'buy,' citing improving earnings quality and a more favorable valuation following a period of underperformance.
Shares in Arcadis (AS:ARDS) jumped more than 5% on Friday to their highest level in nine months after analysts at Jefferies upgraded the Dutch engineering consultancy to "buy." The firm cited an expected recovery in earnings and a more attractive valuation as key drivers for the improved rating.
The stock climbed to €41.38, its highest price since late October, significantly outperforming the broader AEX index, which was up 0.3%, according to the source report.
Jefferies Cites Margin Recovery
In its note to clients, Jefferies raised its price target on Arcadis to €48 from a previous €39.50, representing a potential upside of approximately 22% from Thursday's closing price. The upgrade was based on the view that the company's risk-reward profile has become more favorable.
Analysts at the firm believe that Arcadis's restructuring program and cost-cutting initiatives are beginning to translate into better operating performance. They anticipate that margins will recover as benefits from workforce reductions, overhead savings, and more selective project bidding materialize in the coming quarters.
AdStrategic Outlook and Valuation
Jefferies stated that stronger execution should help mitigate persistent weakness in the company's property and investment division. The firm also highlighted Arcadis's strong position to capitalize on long-term demand trends in several key sectors:
- Water infrastructure
- Energy transition
- Environmental services
- Digital engineering
Despite these structural tailwinds and an improving project pipeline, Jefferies argued that Arcadis shares trade at an "unjustified discount" compared to European engineering peers, suggesting room for a further rerating. The company's second-quarter results, scheduled for July 30, are seen as the next major catalyst for the stock.
Read next
More on Stocks
Nanexa Shares Soar Over 100% After Securing Licensing Pact with Novo Nordisk
Shares of Swedish biotech firm Nanexa AB surged after it announced a global licensing agreement with Novo Nordisk potentially worth up to €1.165 billion for its PharmaShell drug-delivery platform.

IREN Stock Slides as Competitor's IPO Filing Pressures AI Infrastructure Sector
Shares of IREN slid more than 5% amid a sector-wide selloff in AI cloud providers, sparked by a competitor's IPO filing that has raised investor concerns over valuations and pricing power.

Super Micro Computer Stock Climbs on NVIDIA Vera Rubin System Shipments
Shares of Super Micro Computer advanced after the company announced it began shipping its new liquid-cooled rack systems featuring NVIDIA's latest Vera Rubin architecture, a key milestone for its AI infrastructure business.

Celestica Stock Climbs on Pre-Earnings Optimism and Positive Analyst Sentiment
Celestica shares gained nearly 1% as investors positioned ahead of late October's Q3 earnings report and Investor Day. The advance is supported by positive analyst ratings and a strong market narrative around the company's role in AI infrastructure.